Novo Nordisk

293.00 DKK

+2.48 %

1,032 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

+2.48 %
+23.68 %
+4.40 %
-9.92 %
-2.67 %
-36.18 %
-46.44 %
+27.60 %
+23,434.14 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.31T DKK
Turnover
4.56B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
12.71
Dividend yield-%
3.99 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/5
2026

Interim report Q1'26

5/8
2026

Interim report Q2'26

4/11
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Defensive victory. I am officially declaring the end of my Novo-bearishness here. Based on the opening rounds, Wegovy vs Foundayo looks to be a win for Denmark.
7 hours ago
by Clark kent
27
The eternal Novo vs. Eli battle: a data point picked up from Reddit today The launch of the Novo pill has been significantly better.
yesterday
by luettelo
26
Below is an article about how the strong start of Novo’s Wegovy tablet has reportedly revolutionized the weight-loss drug market, while challenging Lilly’s previous dominance in this field. Oral GLP-1 drugs are expanding the market significantly by attracting new user groups with...
yesterday
by Sijoittaja-alokas
26
Novo Nordisk News Details Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased by 4% at CER, driven...
10 hours ago
25
In my opinion, Novo’s pill launch is a major success, and we will soon know how it affects the company’s figures. Sentiment regarding Novo is currently so poor that the Q1 earnings report could turn it around. Hopefully, Novo can regain market share with the pill and win this round...
yesterday
by Ränta på ränta
24
Novo Nordisk’s results a pleasant surprise for a change — One drug rose above the rest Novo Nordisk is raising its guidance following a surprisingly strong first quarter. Tärkeimmät talousuutiset | Kauppalehti – 6 May 26 Novo Nordiskin tulos vaihteeksi iloinen yllätys – Yksi lääke...
7 hours ago
by Index
18
It’s a bit strange to compare Novo to Nokia, as you’d really have to scramble to find any similarities. Nokia killed its mobile business all on its own through the actions of its own leaders. The company’s management had completely lost their understanding of the market and focused...
8 hours ago
by Kari Kokkonen
15
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.